Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-19-002962
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-01-08 21:24:26
Reporting Period:
2019-01-04
Accepted Time:
2019-01-08 21:24:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1567514 Intra-Cellular Therapies Inc. ITCI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1521548 Michael Halstead C/o Intra-Cellular Therapies, Inc.
430 East 29Th Street
New York NY 10016
Evp And General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-01-04 3,108 $0.00 24,757 No 4 M Direct
Common Stock Disposition 2019-01-04 16,060 $11.34 8,697 No 4 S Direct
Common Stock Disposition 2019-01-04 5,398 $11.80 3,299 No 4 S Direct
Common Stock Disposition 2019-01-07 3,108 $12.42 191 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2019-01-04 3,108 $0.00 3,108 $0.00
Common Stock Stock Option (right to buy) Acquisiton 2019-01-08 80,951 $0.00 80,951 $12.73
Common Stock Restricted Stock Units Acquisiton 2019-01-08 58,915 $0.00 58,915 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
80,951 2029-01-07 No 4 A Direct
58,915 No 4 A Direct
Footnotes
  1. Restricted stock units convert into common stock on a one-for-one basis.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2018. A majority of the proceeds from these sales will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.76 to $11.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.77 to $11.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.08 to $12.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  6. Each restricted stock unit represents a contingent right to receive one share of common stock.
  7. On January 4, 2016, the reporting person was granted 9,323 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
  8. On January 8, 2019, the reporting person was granted options to purchase 80,951 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
  9. On January 8, 2019, the reporting person was granted 58,915 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.